Questions to the Committee
1. It is proposed to collect DNA samples
from all participants in clinical trials.
What issues or barriers should be
addressed to facilitate routine
collection of DNA samples?
When (under what circumstances,
to what degree), should DNA be
collected during drug development
for use in exploratory analysis?